Tolvaptan Therapy Duration and Monitoring Guidelines

ADPKD Treatment Duration

Tolvaptan should be used as a long‑term, continuous therapy in autosomal dominant polycystic kidney disease (ADPKD) and continued until the patient approaches the need for kidney replacement therapy. 1
Therapy may be maintained indefinitely with appropriate monitoring, even when estimated glomerular filtration rate falls below 25 mL/min/1.73 m², provided the drug is well tolerated. 2, 3
Patients older than 55 years may continue treatment if tolerability criteria are met. 2, 3

Perform monthly liver function tests for the first 18 months of therapy. 1, 2
After the initial 18 months, conduct liver function testing every 3 months until the drug is discontinued. 1, 3
Obtain a morning blood sample before each tolvaptan dose to assess baseline laboratory values. 1
Monitor serum sodium regularly to evaluate adequacy of water intake and aquaresis. 1, 2

Temporary interruption is recommended when patients experience volume depletion, limited access to water, increased fluid losses, or are engaged in activities in warm weather conditions. 1
Permanent discontinuation is required if liver enzymes rise to ≥ 3 × the upper limit of normal (ULN) without an alternative explanation. 3
Permanent discontinuation is also mandated for signs or symptoms of hepatic injury with ALT/AST > 2 × ULN. 4
Presence of multiple hepatic‑related symptoms (e.g., fatigue, nausea, vomiting, right‑upper‑quadrant pain, jaundice) necessitates permanent drug cessation. 4

Tolvaptan use for hyponatremia is strictly limited to a maximum of 30 days of therapy. 1

The 30‑day limit for hyponatremia is imposed because of the significant risk of hepatotoxicity; long‑term use is not recommended for this indication. 1
Hyponatremia patients require close serum‑sodium monitoring throughout the brief treatment period, whereas ADPKD patients need intensive monthly liver monitoring for the first 18 months followed by quarterly assessments thereafter. 1